News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
484,180 Results
Type
Article (8037)
Company Profile (140)
Press Release (476098)
Multimedia
Podcasts (4)
Webinars (6)
Section
Business (166761)
Career Advice (305)
Deals (25741)
Drug Delivery (7)
Drug Development (52875)
Employer Resources (14)
FDA (9761)
Job Trends (8575)
News (238245)
Policy (17922)
Tag
2027 Biotech Bay Elite (2)
2027 Biotech Bay Standard (4)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (485)
Accelerated approval (24)
ADA (18)
Adcomms (1)
Allergies (96)
Alliances (33154)
ALS (104)
Alzheimer's disease (973)
Antibody-drug conjugate (ADC) (262)
Approvals (10365)
Artificial intelligence (318)
ASCO (159)
Autoimmune disease (205)
Automation (28)
Bankruptcy (262)
Best Places to Work (6958)
BIO (36)
BIOSECURE Act (1)
Biosimilars (108)
BioSpace Insights (17)
Biotechnology (88)
Bladder cancer (138)
Brain cancer (28)
Breast cancer (505)
Cancer (3620)
Cardiovascular disease (217)
Career advice (245)
Career pathing (1)
CAR-T (172)
Celiac Disease (1)
Cell therapy (475)
Cervical cancer (34)
Clinical research (47831)
Collaboration (1234)
Commercialization (3)
Compensation (1440)
Complete response letters (34)
COVID-19 (754)
CRISPR (63)
C-suite (735)
Cystic fibrosis (85)
Data (5597)
Denatured (4)
Depression (102)
Dermatology (60)
Diabetes (340)
Diagnostics (4174)
Digital health (37)
Diversity (1)
Diversity, equity & inclusion (4)
Drug discovery (154)
Drug pricing (7)
Drug shortages (2)
Duchenne muscular dystrophy (163)
Earnings (73526)
Editorial (1)
Employer branding (2)
Employer resources (14)
Events (87572)
Executive appointments (696)
FDA (12357)
Fibrodysplasia Ossificans Progressiva (8)
Friedreich's ataxia (18)
Frontotemporal dementia (23)
Funding (904)
Gene editing (125)
Generative AI (9)
Gene therapy (315)
GLP-1 (289)
Government (940)
Grass and pollen (2)
Guidances (281)
Healthcare (9311)
Hematology (94)
HIV (52)
Huntington's disease (22)
IgA nephropathy (64)
Immunology and inflammation (98)
Immuno-oncology (56)
Indications (155)
Infectious disease (942)
Inflammatory bowel disease (126)
Inflation Reduction Act (4)
Influenza (84)
Intellectual property (251)
Interviews (41)
IPO (12385)
IRA (2)
Job creations (1968)
Job search strategy (235)
JPM (1)
Kidney cancer (16)
Layoffs (59)
Legal (5195)
Licensing (7)
Liver cancer (44)
Longevity (15)
Lung cancer (501)
Lymphoma (249)
Machine learning (27)
Management (3)
Manufacturing (525)
Marketing (8)
MASH (117)
Medical device (8649)
Medtech (8789)
Mergers & acquisitions (14377)
Metabolic disorders (701)
mRNA (53)
Multiple sclerosis (102)
NASH (4)
Neurodegenerative disease (220)
Neuropsychiatric disorders (38)
Neuroscience (1815)
NextGen: Class of 2026 (3150)
Non-profit (841)
Obesity (222)
Opinion (10)
Ovarian cancer (158)
Pain (170)
Pancreatic cancer (195)
Parkinson's disease (201)
Partnered (11)
Patents (466)
Patient recruitment (499)
Peanut (31)
People (41200)
Pharmaceutical (30)
Pharmacy benefit managers (8)
Phase 1 (15452)
Phase 2 (21365)
Phase 3 (14384)
Pipeline (7084)
Policy (18)
Postmarket research (1570)
Preclinical (6534)
Press Release (34)
Prostate cancer (189)
Psychedelics (7)
Radiopharmaceuticals (189)
Rare diseases (568)
Real estate (3019)
Recruiting (6)
Regulatory (14776)
Reports (19)
Research institute (580)
Resumes & cover letters (45)
Rett syndrome (41)
RNA editing (5)
RSV (48)
Schizophrenia (99)
Series A (152)
Series B (119)
Service/supplier (5)
Sickle cell disease (62)
Spinal muscular atrophy (88)
Sponsored (5)
Startups (2018)
Stomach cancer (3)
Supply chain (50)
Vaccines (317)
Venture capital (17)
Weight loss (73)
Women's health (78)
Date
Today (71)
Last 7 days (499)
Last 30 days (1598)
Last 365 days (19185)
2026 (11816)
2025 (19251)
2024 (22987)
2023 (26538)
2022 (34587)
2021 (37168)
2020 (33479)
2019 (23256)
2018 (17493)
2017 (18765)
2016 (17917)
2015 (24263)
2014 (21679)
2013 (18138)
2012 (20221)
2011 (20441)
2010 (20332)
Location
Africa (228)
Alabama (72)
Alaska (2)
Arizona (299)
Arkansas (11)
Asia (17870)
Australia (2095)
California (11820)
Canada (3106)
China (512)
Colorado (478)
Connecticut (405)
Delaware (206)
Europe (24606)
Florida (1767)
Georgia (371)
Hawaii (3)
Idaho (46)
Illinois (692)
India (48)
Indiana (314)
Iowa (14)
Japan (395)
Kansas (100)
Kentucky (30)
Louisiana (26)
Maine (26)
Maryland (1184)
Massachusetts (7793)
Michigan (306)
Minnesota (558)
Mississippi (4)
Missouri (79)
Montana (20)
Nebraska (11)
Nevada (113)
New Hampshire (60)
New Jersey (2596)
New Mexico (12)
New York (2795)
North Carolina (1259)
North Dakota (4)
Northern California (5911)
Ohio (275)
Oklahoma (14)
Oregon (16)
Pennsylvania (2234)
Puerto Rico (20)
Rhode Island (30)
South America (406)
South Carolina (76)
South Dakota (1)
Southern California (4907)
Tennessee (119)
Texas (1906)
United States (38444)
Utah (357)
Vermont (1)
Virginia (152)
Washington D.C. (38)
Washington State (914)
West Virginia (1)
Wisconsin (73)
484,180 Results for "aditxt inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Aditxt Signed Definitive Agreement Valuing Ignite Proteomics at Approximately $150 Million
June 9, 2026
·
8 min read
Press Releases
Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-27 Reverse Stock Split Effective at the Open of Trading on May 18, 2026
May 14, 2026
·
3 min read
Press Releases
Aditxt, Inc. Appoints Jeffrey M. Busch as Interim Chief Executive Officer; Founder and Former CEO of $1B NYSE Enterprise Which Delivered ~8.5% Dividends to Shareholders
June 2, 2026
·
13 min read
Press Releases
Aditxt Subsidiary Ignite Proteomics Appoints Public Company Veteran Jeff Busch as Chief Executive Officer
March 19, 2026
·
4 min read
Press Releases
Aditxt Acquires Ignite Proteomics to Address a Critical Challenge in Cancer Care: Optimizing Therapy Selection
March 13, 2026
·
7 min read
Press Releases
Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-113 Reverse Stock Split Effective at the Open of Trading on November 3, 2025
October 29, 2025
·
3 min read
Press Releases
Aditxt’s Subsidiary Pearsanta Receives an Invitation to Submit Full Proposal for the U.S. Department of Defense Pilot Award for the Development of its Mitomic® Ovarian Test
July 25, 2025
·
6 min read
Press Releases
Evofem Biosciences’ CEO Saundra Pelletier Joins Aditxt Board of Directors
June 9, 2025
·
5 min read
Press Releases
Aditxt Announces Termination of Arrangement Agreement With Appili Therapeutics
May 19, 2025
·
4 min read
Press Releases
Aditxt’s Subsidiary Adimune Highlights Its Approach to Reprogramming the Immune System Through DNA Instructions, Now with 96 Granted and 22 Pending Patents Targeting Autoimmunity Market Estimated at Over $160 Billion by 2030
August 26, 2025
·
5 min read
1 of 48,418
Next
